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In Western countries, heart failure has become one of the most
prominent health care problems. Increased prevalence of coronary
artery disease (CAD), improvements in CAD and hypertension
treatment, and ageing of the population are major factors contri-
buting to the fact that 1–2% of the Western populations suffer
from heart failure, with a prevalence of 10% or more in the very
elderly. Despite advances in heart failure therapy, morbidity and
mortality remain high and quality of life is severely impaired.1
Heart failure is a leading cause of hospital admissions, and hospital-
izations for heart failure are often of long duration, resulting in
enormous health care costs. It is estimated that they account for
2% of the total health care budget in these countries.
Despite the importance of heart failure, both to the affected
patients and to the health care providers, and much effort in
basic as well as clinical research, many aspects in heart failure
are still incompletely understood. For a long time, the focus was
almost exclusively on systolic dysfunction. Heart failure was con-
sidered as the final common pathway of different cardiac disorders
and, as a consequence, difficult to reverse. Once left ventricular
systolic function is significantly depressed, uniform therapeutic
response and results from human and animal studies suggested
that the underlying cause is of lesser relevance. Therapy focuses
primarily on delay of disease progression and complications of
heart failure, whereas treatment of underlying diseases or risk
factors is the main focus in prevention of heart failure only.2 In
the 1990s, it was recognized that many patients with the clinical
symptom of heart failure do not have left ventricular systolic dys-
function, particularly in the elderly population, where at least half
of the heart failure patients have preserved left ventricular systolic
function.3 Various population-based studies such as the Cardiovas-
cular Health Study have contributed significantly to this
understanding.
In heart failure with preserved left ventricular systolic function,
diastolic dysfunction is considered to be the main cause, but the
pathophysiology behind it is still incompletely understood. Differ-
ent factors are believed to contribute to this.4 Traditional cardio-
vascular risk factors were found to be related to the
development of heart failure with preserved left ventricular systolic
function. Various other factors, some associated with the tra-
ditional risk factors, are recognized to be of importance. Among
those, left ventricular hypertrophy may be of particular signifi-
cance, as it is considered not only to be the result of risk
factors, particularly arterial hypertension, but also to be an inde-
pendent risk factor of both systolic and diastolic left ventricular
dysfunction. As a consequence, left ventricular hypertrophy is
now considered a pre-clinical disease.5
However, to differentiate between left ventricular hypertrophy
being the cause or the result of heart failure may be difficult as
all these factors interact significantly. Thus, little is known about
whether left ventricular hypertrophy is related to incident heart
failure independent of coronary vascular events. de Simone et al.
have provided strong evidence that this is indeed the case.6
They analysed a subgroup of .2000 patients of the Cardiovas-
cular Health Study cohort, who did not have evidence of previous
myocardial infarction. They show that not only load-dependent,
but, possibly more importantly, also load-independent concentric
left ventricular hypertrophy is a strong risk factor for the develop-
ment of heart failure during the upcoming years, independently of
other risk factors. This increased risk was independent of incident
myocardial infarction, suggesting that mechanisms other than myo-
cardial ischaemia and haemodynamic load may play an important
role in the development of heart failure in patients with left ventri-
cular hypertrophy. In addition, this study supports the shifting para-
digm that left ventricular hypertrophy may be detrimental already
in its early stage, and prevention of the hypertrophic response is
actually associated with preserved ventricular function.7
Why is this finding important? The pathophysiological under-
standing of incident heart failure may be enhanced, although data
from a cohort study do not allow direct conclusions. de Simone
et al. discuss potential mechanisms,6 amongst which myocardial
fibrosis may be the central one, also potentially having therapeutic
implications. However, there are numerous other potential mech-
anisms, and a huge variety of pathways were found to be involved
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in animal studies (for a review, see Meijs et al.7). Another import-
ant aspect of the study by de Simone et al. is that their data support
the concept of diastolic and systolic heart failure being a continuum
rather than two different entities, since small changes in systolic
function were observed with increasing hypertrophy despite
overall left ventricular systolic function being in the normal
range. Additionally, left ventricular hypertrophy was associated
with left atrial dilation, which was an independent predictor of inci-
dent heart failure and was found to be an indicator for heart failure
in patients with preserved left ventricular systolic function in
another study.8 Unfortunately, de Simone et al. do not provide
information on further structural and functional changes during
follow-up. This would help to see if left ventricular hypertrophy
per se may directly cause systolic dysfunction, independently of vas-
cular damage. The clinical course of severe aortic stenosis with
progressive deterioration of systolic function in late stages may
be seen as an indicator for this, but hypertrophy in aortic stenosis
is not load independent. Still, increased left ventricular mass in
aortic stenosis predicts the presence of heart failure and may be
maladaptive rather than beneficial.9 Animal studies also support
the concept of hypertrophy being independently associated with
heart failure, but many of these studies did not use physiologically
relevant models, most were in rodents and of very limited dur-
ation.7 Further, in the analysis of de Simone et al., a substantial
number of patients were excluded from their analysis as no suffi-
cient echocardiographic images were available. This may be rel-
evant since it is known that subjects with insufficient
echocardiographic quality differ significantly from those with ade-
quate image quality.10
The question of left ventricular systolic and diastolic dysfunction
being a continuum may be important for new therapeutic targets.
While treatment in systolic dysfunction is well established and
effective,11 treatment of heart failure with preserved left ventricu-
lar systolic function remains challenging. There are only a very
limited number of studies in such patients and most of them
were rather small. Importantly, the only large trial so far, the
CHARM preserved trial,12 failed to show an improvement in
outcome above what would have been expected from the
achieved blood pressure-lowering effect. The reason for lack of sig-
nificant outcome improvement is not clear, but diagnosing diastolic
dysfunction is difficult and not well defined. In CHARM preserved,
it was mainly a clinical diagnosis,12 and some of the patients
included, therefore, may not have had heart failure. This assump-
tion is supported by the recently published CHARM echocardio-
graphic substudy in preserved left ventricular systolic function,
where only two-thirds of patients had objective evidence of dias-
tolic dysfunction and only in less than half of them was it truly rel-
evant.13 In addition, underlying causes and pathophysiological
mechanisms of heart failure with preserved left ventricular systolic
function may not be uniform and may be more relevant in the
treatment of these patients compared with systolic dysfunction.
The question remains whether therapy-induced regression of
left ventricular hypertrophy is associated with a direct effect on
prognosis and prevention of heart failure. It is well established
that antihypertensive therapy leads to both regression of left ven-
tricular hypertrophy and improvement in prognosis.14 Again, it is
very difficult to differentiate between a direct therapeutic effect
on hypertrophy and associated prognostic improvement and an
indirect effect by reduction of vascular events. Interestingly, indir-
ect evidence from the HOPE trial suggests that regression of left
ventricular hypertrophy may result in a larger reduction in heart
failure events than in myocardial infarctions.15 Animal studies
suggest that inhibition of neurohumoral stimulation such as
the sympathetic nervous system and the renin–angiotensin–
aldosterone system may provide a beneficial effect on left ventricu-
lar hypertrophy, remodelling, and diastolic function independently
of blood pressure lowering.16 Still further studies, particularly in
humans, are required to address this question more specifically.
Complete follow-up including detailed information on medication
at different time points in large cohort studies may also add to
the understanding.
The task of understanding the mechanisms of heart failure, par-
ticularly at the very early stage and in patients with preserved left
ventricular systolic function, is complex. Many contributing factors
are known, but, as all interact significantly, their importance is not
well known. Studies such as the one by de Simone et al.6 may help
to shed further light on this as it aims to differentiate contributing
factors. However, there is still much to be done.
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